Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
TALWIN (pentazocine lactate) is an injectable opioid analgesic approved in 1967 for moderate to severe pain management. It is a mixed opioid agonist-antagonist that provides pain relief through central nervous system mechanisms. The product is administered via injection and remains in use for acute pain settings where parenteral analgesia is required.
As an established injectable opioid facing approaching loss of exclusivity, the brand team is likely in defensive/maintenance mode with modest headcount focused on retention and deprescribing compliance.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TALWIN at this stage of its lifecycle offers limited upside for career acceleration; roles focus on defending market share, managing compliance, and preparing for post-LOE transition. This is better suited to mid-career professionals seeking stability or those building specialized expertise in opioid stewardship and deprescribing initiatives.
Worked on TALWIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.